Literature DB >> 9921932

Treated plasma cell lesions of bone with MRI signs of response to treatment: unexpected pathological findings.

F E Lecouvet1, P De Nayer, C Garbar, H Noël, J Malghem, B E Maldague, B C Vande Berg.   

Abstract

Two cases of treated plasma cell lesions of bone are reported for which contrast-enhanced MRI had suggested necrosis, based on lack of enhancement after gadolinium injection, and in which pathologic examinations revealed the presence of extensive viable neoplastic tissue. These cases highlight the need for cautious interpretation of contrast-enhanced MRI signs of response to treatment and inactivity of lesions in the setting of plasma cell neoplasms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9921932     DOI: 10.1007/s002560050461

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  6 in total

1.  Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma.

Authors:  Richard J Breyer; Michael E Mulligan; Stacy E Smith; Bruce R Line; Ashraf Z Badros
Journal:  Skeletal Radiol       Date:  2006-06-07       Impact factor: 2.199

2.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2004-01-14       Impact factor: 3.909

Review 3.  MRI for response assessment in metastatic bone disease.

Authors:  F E Lecouvet; A Larbi; V Pasoglou; P Omoumi; B Tombal; N Michoux; J Malghem; R Lhommel; B C Vande Berg
Journal:  Eur Radiol       Date:  2013-03-01       Impact factor: 5.315

Review 4.  PET/CT and MR imaging in myeloma.

Authors:  Michael E Mulligan; Ashraf Z Badros
Journal:  Skeletal Radiol       Date:  2006-08-17       Impact factor: 2.199

Review 5.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

6.  Problems monitoring response in multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.